Search
Immunotherapies have revolutionized cancer treatment. In particular, immune checkpoint therapy (ICT) leads to durable responses in some patients with some cancers. However, the majority of treated patients do not respond. Understanding immune mechanisms that underlie responsiveness to ICT will help identify predictive biomarkers of response and develop treatments to convert non-responding patients to responding ones. ICT primarily acts at the level of adaptive immunity. The specificity of adaptive immune cells, such as T and B cells, is determined by antigen-specific receptors.
There is a strong unmet need to improve systemic therapy in mesothelioma. Chemotherapy with cisplatin and pemetrexed improves survival in malignant pleural mesothelioma, and immune checkpoint inhibitors are an emerging treatment in this disease. We aimed to evaluate the activity of durvalumab, an anti-PD-L1 antibody, given during and after first-line chemotherapy with cisplatin and pemetrexed in patients with advanced malignant pleural mesothelioma.
Acute erythroleukemia (AEL or acute myeloid leukemia [AML]-M6) is a rare but aggressive hematologic malignancy. Previous studies showed that AEL leukemic cells often carry complex karyotypes and mutations in known AML-associated oncogenes.
Transcription factors known to induce the epithelial-to-mesenchymal transition (EMT) (such as ZEB1/2 [zinc finger E-box binding homeobox 1/2], SNAI1/2/3, and TWIST1/2) have been undoubtedly implicated in tumorigenesis, cancer progression, metastasis, and chemoresistance in solid tumors; however, their role in normal and malignant hematopoiesis has been underappreciated for many years.
Children with aggressive brain cancers could soon have access to a significant new treatment option, using a unique antibody that stops cancer cells from repairing themselves.
The Kids Research Institute Australia researcher, Dr Anya Jones, will join some of the world’s brightest female scientists after being selected to take part in a global project to amplify the voices of women in science leadership.
Cancer Council WA has awarded a Post-Doctoral Fellowship to Dr Ben Wylie, for his project to help kids with sarcoma.
It is the kids he treats in his role as a paediatric oncologist that motivate Dr Nick Gottardo in his work as a The Kids Research Institute Australia cancer researcher.
The Global Symposium on Childhood Brain Tumours is bringing the world's premier childhood brain tumour researchers and scientists together in Perth.
A The Kids study examining drug resistance in leukaemia patients has shed new light on why some treatments may be more effective than others.